![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Hands AstraZeneca, Daiichi Sankyo’s Breast Cancer Drug Priority Review
FDA Hands AstraZeneca, Daiichi Sankyo’s Breast Cancer Drug Priority Review
October 31, 2019
The FDA granted AstraZeneca and Daiichi Sankyo’s breast cancer biologic trastuzumab deruxtecan a priority review for HER2-positive metastatic breast cancer.
AZ’s executive vice president of oncology R&D, José Baselga, said the antibody drug conjugate “has the potential to transform the treatment landscape for patients with HER2-positive metastatic breast cancer” that only have limited treatment options available.
The treatment previously received the agency’s breakthrough therapy and fast track designations.
Upcoming Events
-
21Oct